Skip to main content

Movement disorders

Angelo Antonini

24-05-2020 | Parkinson's disease | Video

EAN 2020 | Impulsivity underestimated in Parkinson’s disease

Angelo Antonini presents real-world data from the PRISM study, highlighting the prevalence of impulse control disorders in patients with Parkinson’s disease and their association with dopamine agonists (5:34).

Tayyabah Yousaf

02-07-2019 | Parkinson's disease | Video

EAN 2019: Grey matter volume increased in GBA mutation carriers prior to parkinsonian onset

Tayyabah Yousaf reports on findings that glucocerebrosidase gene mutations are associated with structural cerebral abnormalities even in the absence of clinical manifestations of Parkinson’s disease (2:38).

Oliver Cousins

01-07-2019 | Parkinson's disease | Video

EAN 2019: Semantic fluency impairment may predict Parkinson’s disease dementia

Oliver Cousins summarizes his research highlighting semantic fluency impairment and underlying amygdala atrophy as predictive factors of cognitive decline in patients with Parkinson’s disease (3:58).

Tatyana Simuni

08-05-2019 | Parkinson's disease | Video

AAN 2019: LRRK2, GBA carriers exhibit subtle manifestations of Parkinson’s disease

Tatyana Simuni describes the clinical and imaging features of LRRK2 and GBA mutation carriers participating in the Parkinson's Progression Markers Initiative cohort (6:29).

31-01-2019 | Parkinson's disease | News | Article

Early levodopa treatment not justified in Parkinson’s disease

Levodopa does not modify Parkinson’s disease, show study findings suggesting there is no benefit to starting the drug early in the disease course.

01-11-2018 | Parkinson's disease | News | Article

Dopamine to levodopa-carbidopa switch reduces impulse control disorders in PD

Switching from dopamine agonists to levodopa-carbidopa slow-release formulations reduces impulse control disorders in patients with Parkinson’s disease, shows a multicentre study.